ClinicalTrials.gg
CompletedNCT07010406Updated Sep 18, 2025

A Study to Evaluate the Relative Bioavailability of Povetacicept Formulations and Bioequivalence of Povetacicept Presentations

A Phase 1 interventional study of Povetacicept in Healthy Volunteers, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 2 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-18.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2025, 1 year 2 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
136
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the relative bioavailability of Povetacicept formulations, bioequivalence of Povetacicept presentations, and safety and tolerability of Povetacicept.

Read the detailed description

This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.).

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Vertex Pharmaceuticals Incorporated is the lead sponsor of 249 studies on the registry; 17 are open to participants now.

Of its 107 completed or terminated interventional studies of FDA-regulated products, 54 (50%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • (BMI) of 18.0 to 32.0 kilogram per meter square (kg/m\^2), inclusive
  • A total body weight of more than (>) 50 kg

Key Exclusion Criteria:

  • History of febrile illness that has not fully resolved within 14 days before the dose of study drug.
  • Immunization with a within 45 days before study drug administration or a non live vaccine within 14 days before study drug administration.

Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
136 participants (actual)

Study arms

  • Experimental
    Part A1: Povetacicept Bioavailability

    Participants will be randomized to receive one of the two Povetacicept formulations.

    Drug: Povetacicept

  • Experimental
    Part A2: Povetacicept Bioavailability

    Participants will be randomized to receive one of the two Povetacicept formulations.

    Drug: Povetacicept

  • Experimental
    Part B1: Povetacicept Bioequivalence

    Participants will be randomized to receive one of the two Povetacicept presentations.

    Drug: Povetacicept

  • Experimental
    Part B2: Povetacicept Bioequivalence

    Participants will be randomized to receive one of the two Povetacicept presentations.

    Drug: Povetacicept

Interventions

06

What researchers measure

Primary outcomes

  1. Area Under the Concentration Versus Time Curve From the Time of Dosing to 28 Days (AUC0-28d) of Free Povetacicept

    Time frame: From Day 1 up to Day 30

  2. Maximum Observed Plasma Concentration (Cmax) of Free Povetacicept

    Time frame: From Day 1 up to Day 30

Secondary outcomes

  1. Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: From Day 1 up to Day 31

07

Study locations

2 sites
  • Celerion - Tempe
    Tempe, Arizona 85283, United States
  • Celerion - Lincoln
    Lincoln, Nebraska 68502, United States
08

References and documents

Individual participant data

Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2025 to primary completion in Aug 2025, 2 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 30, 2025
First posted
Jun 8, 2025
StartActual
Jun 6, 2025
Primary completionActual
Aug 19, 2025
CompletionActual
Aug 19, 2025
Last update
Sep 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07010406
Responsible party
Sponsor
First posted
Jun 8, 2025
Start date
Jun 6, 2025
Primary completion
Aug 19, 2025
Completion
Aug 19, 2025
Last update
Sep 18, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Povetacicept

Start the discussion